MedTrace Logo

The Effect of Glucose Level and Diabetes Mellitus on Ctrough of Olaparib

NCT05081765 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-10-18

No results posted yet for this study

Summary

Monitored therapy of olaparib concentrations in the blood of diabetic population probably will assess the need for individual dosing of the drug.

The project concerns on the monitored therapy of olaparib in a population of patients with DM, hyperglycemia and normal glucose level.

Currently, there are no studies assessing the effect of comorbidities and of the administered drugs on the pharmacokinetics of olaparib.

Conditions

  • Ovary Cancer

Interventions

DRUG

Lynparza® (AstraZeneca Pharma Poland Sp. z o.o.)

correlation between C through and taken drug

DEVICE

Lynparza

correlation between C through and taken drug

Sponsors & Collaborators

  • Poznan University Hospital of Lord's Transfiguration

    collaborator OTHER

  • Poznan University of Medical Sciences

    lead OTHER

Principal Investigators

  • Joanna J Stanisławiak - Rudowicz · University of Medical Sciences Poznań, Poland

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-20
Primary Completion
2022-10-15
Completion
2022-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05081765 on ClinicalTrials.gov